Industry Dynamics: 2010 Guide to the Asia-Pacific Life Sciences Industry
License Price: US$ 7,490.00
Introduction
Pharmaceutical companies are expanding into the Asia-Pacific region to increase their market share and reduce costs. The life sciences industry is difficult enough for technology vendors to enter, but add to it the complexity of emerging markets, and the process can be downright overwhelming. Ovum provides an introduction to the life sciences in APAC in order for vendors to penetrate the market.
Features and benefits
Before attempting to penetrate the APAC pharma market, it is important to understand the complexity of the global life sciences industry. Once vendors understand the industry as a whole, they will better comprehend the dynamics of the APAC markets and how the developed and emerging pharma industries fit into their customers' global strategies.The Asia-Pacific life sciences industry varies greatly, comprised of both developed and emerging markets. It is also home to small, emerging biotech companies with up to ten employees as well as Big Pharma with thousands of employees. As wide as the spectrum is for size and type of life sciences company, so is the need for IT solutions.The emerging markets have seen tremendous growth, and this trend will likely continue, but not without the help of key IT solutions. The APAC pharma and biotech sectors are much more open to the use of IT that their Western counterparts, but it is still important for technology vendors to understand where and how to best realize success.
Your key questions answered
Introduction
Pharmaceutical companies are expanding into the Asia-Pacific region to increase their market share and reduce costs. The life sciences industry is difficult enough for technology vendors to enter, but add to it the complexity of emerging markets, and the process can be downright overwhelming. Ovum provides an introduction to the life sciences in APAC in order for vendors to penetrate the market.
Features and benefits
- Offers an overview of the pharmaceutical and biotechnology sectors in Australia, China, India, and Japan
- Discusses key areas where there is greatest need for technology in the APAC life sciences industry
- Provides go-to-market strategies to help vendors enter the APAC pharma and biotech markets and realize successful
Before attempting to penetrate the APAC pharma market, it is important to understand the complexity of the global life sciences industry. Once vendors understand the industry as a whole, they will better comprehend the dynamics of the APAC markets and how the developed and emerging pharma industries fit into their customers' global strategies.The Asia-Pacific life sciences industry varies greatly, comprised of both developed and emerging markets. It is also home to small, emerging biotech companies with up to ten employees as well as Big Pharma with thousands of employees. As wide as the spectrum is for size and type of life sciences company, so is the need for IT solutions.The emerging markets have seen tremendous growth, and this trend will likely continue, but not without the help of key IT solutions. The APAC pharma and biotech sectors are much more open to the use of IT that their Western counterparts, but it is still important for technology vendors to understand where and how to best realize success.
Your key questions answered
- Understand the pharmaceutical and biotechnology product lifecycle and business processes
- Identify emerging areas of concern for pharmaceutical and biotechnology companies, particularly in Australia, China, India and Japan
- Gain insight into what solutions and services will appeal most to APAC life sciences companies
SUMMARY
Catalyst
Ovum view
Key messages
Understand the complexity of the global life sciences industry before attempting to penetrate the APAC pharma market
The Asia-Pacific life sciences industry varies greatly and comprises both developed and emerging markets
IT will have an immense impact on the growth of the Asia-Pacific pharma industry
UNDERSTANDING THE PHARMA PROCESS
About the industry
The drug discovery and development process is long and expensive
Discovery and pre-clinical research
Clinical research
Manufacturing
Sales and marketing
The biggest challenge facing the pharma industry is the successful navigation of the 2011 patent cliff
THE APAC LIFE SCIENCES MARKET
Overview of APAC markets
Australia's pharmaceutical market
China's pharmaceutical market
Hong Kong operates separately from mainland China
India's pharmaceutical market
Japan's pharmaceutical market
Slowing growth in major developed markets drives pharma M&A in APAC
Trends within countries based on the process areas
Discovery and pre-clinical research
Clinical trials
Manufacturing
Sales and marketing
OPPORTUNITIES FOR TECHNOLOGY VENDORS
How best to capitalize
The pharma product lifecycle plays a crucial role in IT strategy
APAC's developed markets have a more short-term view on research-enabling IT investment than their emerging counterparts
To reduce the most expensive aspect of drug development, pharma companies are investing in e-clinical technologies
APAC and drug manufacturing: one cannot be mentioned without the other
The patent cliff has a big impact on the APAC sales and marketing landscape
The majority of a life sciences company's IT budget is allocated to a few core solutions
IT engagement with pharma comes with its own set of dynamics
The lifecycle approach to technology is important, but don't forget the stack
APAC pharma companies will spend more on hardware and software than their global peers
Cloud computing is seen as a way to scale quickly
The CIO is still king, but be wary of the CFO
With no two life sciences markets exactly the same, neither is their IT investment
Big Pharma has the greatest impact on Australia's pharma IT sector, but smaller companies need to be heard as well
The greatest short-term and long-term opportunities reside in China
As the Indian market moves towards new drug R&D, investment in IT will grow
High-tech Japan will continue to invest in IT, but growth will be limited
RECOMMENDATIONS FOR TECHNOLOGY VENDORS
The right solutions for the right processes
Position technology along the pharma lifecycle
Know the pharma company's product pipeline and drug portfolio
Route to market will be a critical success factor
Keep in mind that IT budget allocation does not equal priority
Focus on IT solutions that enable the shift towards biotech research
APPENDIX
Definitions
Further reading
Methodology
Ovum authors
Datamonitor author
Ovum Consulting
Disclaimer
Catalyst
Ovum view
Key messages
Understand the complexity of the global life sciences industry before attempting to penetrate the APAC pharma market
The Asia-Pacific life sciences industry varies greatly and comprises both developed and emerging markets
IT will have an immense impact on the growth of the Asia-Pacific pharma industry
UNDERSTANDING THE PHARMA PROCESS
About the industry
The drug discovery and development process is long and expensive
Discovery and pre-clinical research
Clinical research
Manufacturing
Sales and marketing
The biggest challenge facing the pharma industry is the successful navigation of the 2011 patent cliff
THE APAC LIFE SCIENCES MARKET
Overview of APAC markets
Australia's pharmaceutical market
China's pharmaceutical market
Hong Kong operates separately from mainland China
India's pharmaceutical market
Japan's pharmaceutical market
Slowing growth in major developed markets drives pharma M&A in APAC
Trends within countries based on the process areas
Discovery and pre-clinical research
Clinical trials
Manufacturing
Sales and marketing
OPPORTUNITIES FOR TECHNOLOGY VENDORS
How best to capitalize
The pharma product lifecycle plays a crucial role in IT strategy
APAC's developed markets have a more short-term view on research-enabling IT investment than their emerging counterparts
To reduce the most expensive aspect of drug development, pharma companies are investing in e-clinical technologies
APAC and drug manufacturing: one cannot be mentioned without the other
The patent cliff has a big impact on the APAC sales and marketing landscape
The majority of a life sciences company's IT budget is allocated to a few core solutions
IT engagement with pharma comes with its own set of dynamics
The lifecycle approach to technology is important, but don't forget the stack
APAC pharma companies will spend more on hardware and software than their global peers
Cloud computing is seen as a way to scale quickly
The CIO is still king, but be wary of the CFO
With no two life sciences markets exactly the same, neither is their IT investment
Big Pharma has the greatest impact on Australia's pharma IT sector, but smaller companies need to be heard as well
The greatest short-term and long-term opportunities reside in China
As the Indian market moves towards new drug R&D, investment in IT will grow
High-tech Japan will continue to invest in IT, but growth will be limited
RECOMMENDATIONS FOR TECHNOLOGY VENDORS
The right solutions for the right processes
Position technology along the pharma lifecycle
Know the pharma company's product pipeline and drug portfolio
Route to market will be a critical success factor
Keep in mind that IT budget allocation does not equal priority
Focus on IT solutions that enable the shift towards biotech research
APPENDIX
Definitions
Further reading
Methodology
Ovum authors
Datamonitor author
Ovum Consulting
Disclaimer
TABLES
Table: Pharmaceutical and biotechnology industry sub-segments
Table: Key population, healthcare expenditure and pharmaceutical and biotechnology market indicators for APAC
Table: Sales growth for the leading pharmaceutical and biotechnology companies in APAC, 2005-9
Table: Pharmaceutical and biotechnology industry sub-segments
Table: Key population, healthcare expenditure and pharmaceutical and biotechnology market indicators for APAC
Table: Sales growth for the leading pharmaceutical and biotechnology companies in APAC, 2005-9
FIGURES
Figure: The drug discovery and development lifecycle
Figure: The drug discovery and pre-clinical research processes
Figure: The clinical trials process
Figure: SCOR: Capturing the pharma manufacturing process
Figure: Stakeholders involved in pharma sales and marketing
Figure: The sales and marketing process through shelf-time
Figure: Loss in sales due to generic erosion from brands expiring between 2010 and 2014
Figure: Heat map of discovery and pre-clinical research activity in APAC
Figure: Heat map of clinical trial activity in APAC
Figure: Heat map of manufacturing activity in APAC
Figure: Heat map of sales and marketing activity in APAC
Figure: The pharma business processes and associated IT solutions
Figure: Heat map of research IT adoption in APAC over five years
Figure: Heat map of clinical research IT adoption in APAC over five years
Figure: Heat map of manufacturing IT adoption in APAC over five years
Figure: Heat map of sales and marketing IT adoption in APAC over five years
Figure: Percentage of IT budget allocated to various technology solutions
Figure: Pharma IT budget allocations by technology category
Figure: Cloud computing adoption plans in pharma companies
Figure: Influence of C-level executives on IT investment
Figure: Australia's IT spending by life sciences sector, 2009-2015
Figure: China's IT spending by life sciences sector, 2009-2015
Figure: India's IT spending by life sciences sector, 2009-2015
Figure: Japan's IT spending by life sciences sector, 2009-2015
Figure: Priority of technology solution for IT budget allocation
Figure: The drug discovery and development lifecycle
Figure: The drug discovery and pre-clinical research processes
Figure: The clinical trials process
Figure: SCOR: Capturing the pharma manufacturing process
Figure: Stakeholders involved in pharma sales and marketing
Figure: The sales and marketing process through shelf-time
Figure: Loss in sales due to generic erosion from brands expiring between 2010 and 2014
Figure: Heat map of discovery and pre-clinical research activity in APAC
Figure: Heat map of clinical trial activity in APAC
Figure: Heat map of manufacturing activity in APAC
Figure: Heat map of sales and marketing activity in APAC
Figure: The pharma business processes and associated IT solutions
Figure: Heat map of research IT adoption in APAC over five years
Figure: Heat map of clinical research IT adoption in APAC over five years
Figure: Heat map of manufacturing IT adoption in APAC over five years
Figure: Heat map of sales and marketing IT adoption in APAC over five years
Figure: Percentage of IT budget allocated to various technology solutions
Figure: Pharma IT budget allocations by technology category
Figure: Cloud computing adoption plans in pharma companies
Figure: Influence of C-level executives on IT investment
Figure: Australia's IT spending by life sciences sector, 2009-2015
Figure: China's IT spending by life sciences sector, 2009-2015
Figure: India's IT spending by life sciences sector, 2009-2015
Figure: Japan's IT spending by life sciences sector, 2009-2015
Figure: Priority of technology solution for IT budget allocation
